US 11,701,402 B2
Polypharmaceutical drug compositions and related methods
Parag G. Mehta, Burlington, MA (US); Sharmila Mudgal, Lexington, MA (US); Lal Hingorani, Maharashtra (IN); and Luis Z. Avila, Arlington, MA (US)
Assigned to Aveta Biomics, Inc., Bedford, MA (US)
Appl. No. 17/44,696
Filed by Aveta Biomics, Inc., Bedford, MA (US)
PCT Filed Apr. 2, 2019, PCT No. PCT/US2019/025465
§ 371(c)(1), (2) Date Oct. 1, 2020,
PCT Pub. No. WO2019/195349, PCT Pub. Date Oct. 10, 2019.
Claims priority of provisional application 62/651,683, filed on Apr. 2, 2018.
Prior Publication US 2021/0252097 A1, Aug. 19, 2021
Int. Cl. A61K 36/9066 (2006.01); A61K 31/12 (2006.01); A61K 47/44 (2017.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 36/9066 (2013.01) [A61K 31/12 (2013.01); A61K 45/06 (2013.01); A61K 47/44 (2013.01); A61P 35/00 (2018.01)] 17 Claims
 
1. A method of increasing T-cell infiltration in a tumor of a subject, such method comprising a step of administering a pharmaceutical composition to the subject, wherein the composition comprises:
(a) one or more high polarity compounds isolated from Curcuma longa using a high polarity solvent system having a dielectric constant of greater than about 25 and a relative polarity value of greater than about 0.6 and selected from the group consisting of proteins, polysaccharides, and peptides;
(b) one or more medium polarity compounds isolated from Curcuma longa using a medium polarity solvent system having a dielectric constant of about 5 to about 25 and a relative polarity value of about 0.25 to about 0.6 and selected from the group consisting of polyphenols, curcumin, demethoxycurcumin, and bisdemethoxycurcumin; and
(c) one or more non-polar compounds isolated from Curcuma longa using a non-polar solvent system having a dielectric constant of less than about 5 and a relative polarity value of less than about 0.2 and selected from the group consisting of terpenoids, ar-turmerone, α-turmerone, and β-turmerone;
wherein the tumor is oral squamous cell carcinoma.